CYP2C19*17 is associated with decreased breast cancer risk
Authors:
- 3 June 2008
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 115 (2) , 391-396
Abstract
Cytochrome P450 2C19 (CYP2C19) plays an important role in the metabolism of xenobiotics and drugs and contributes to the catabolism of endogenous substrates like estradiol. Genetic variability impacts expression and activity of CYP2C19 and therefore can influence catabolism of estrogens. In the present study we analyzed the association of three polymorphisms of CYP2C19 namely CYP2C19*2 (CYP2C19_681_G>A, rs4244285), CYP2C19*3 (CYP2C19_636_G>A, rs57081121) and CYP2C19*17 (CYP2C19_-806_C>T, rs12248560), with breast cancer susceptibility. We genotyped 1,015 breast cancer cases and 1,021 age-matched, population-based controls of the German GENICA study by matrix assisted laser desorption/ionization time-of-flight mass spectrometry. Risk estimates were calculated by logistic regression. All tests were two-sided. We observed a decreased breast cancer risk for carriers of the CYP2C19*17 allele (OR 0.77, 95% CI: 0.65–0.93; P = 0.005). In subgroup analysis we observed a significant decreased breast cancer risk for women using hormone therapy for ten years or longer who were carriers of the CYP2C19*17 allele (OR 0.57, 95% CI: 0.39–0.83; P = 0.003). Since CYP2C19*17 defines an ultra rapid metabolizer phenotype we suggest that an increased catabolism of estrogens by CYP2C19 may lead to decreased estrogen levels and therefore reduces breast cancer risk. This protective effect seems to be stronger in combination with long-term intake of supplemental estrogens during hormone therapy.Keywords
This publication has 21 references indexed in Scilit:
- Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 GenotypesJournal of Clinical Oncology, 2007
- The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancerBreast Cancer Research and Treatment, 2007
- Breast cancer: a candidate gene approach across the estrogen metabolic pathwayBreast Cancer Research and Treatment, 2007
- Role of Polymorphic Human Cytochrome P450 Enzymes in Estrone OxidationCancer Epidemiology, Biomarkers & Prevention, 2006
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- Factors Modifying the Association Between Hormone-Replacement Therapy and Breast Cancer RiskEuropean Journal of Epidemiology, 2005
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Pharmacogenomics of proton pump inhibitorsPharmacogenomics, 2004
- Breast cancer and hormone-replacement therapy: the Million Women StudyThe Lancet, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002